finance.yahoo.com / Yahoo! Finance
npub1vap…wc3n
2024-11-22 17:09:37
Author Public Key
npub1vap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aessgrwc3nSeen on
wss://articles.layer3.newsPublished at
2024-11-22 17:09:37Event JSON
{
"id": "611b16def72c34b20959d5161211d404f2540d01e2e499422fee6c3df9dc90fb",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1732295377,
"kind": 1,
"tags": [
[
"r",
"https://www.investors.com/news/technology/abbvie-stock-emraclidine-schizophrenia-cerevel-bristol-myers-squibb/?src=A00220\u0026yptr=yahoo"
],
[
"subject",
"AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback"
],
[
"published_at",
"1732293016"
],
[
"image",
"https://media.zenfs.com/en/ibd.com/5f28833afc0a5869fde03794f79126d3"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/ibd.com/5f28833afc0a5869fde03794f79126d3"
],
[
"t",
"other:perspective"
],
[
"summary",
"AbbVie's stock price jumped after an analyst upgraded the company, despite a recent setback in its schizophrenia treatment drug, emraclidine. The analyst, David Risinger, believes that the company's immunology drugs, Skyrizi and Rinvoq, have a huge runway for growth in the US. He also sees potential in the company's Cerevel takeover, which could yield promising drugs in the coming years."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://media.zenfs.com/en/ibd.com/5f28833afc0a5869fde03794f79126d3\n\nhttps://www.investors.com/news/technology/abbvie-stock-emraclidine-schizophrenia-cerevel-bristol-myers-squibb/?src=A00220\u0026yptr=yahoo",
"sig": "b80494a8421fee298706688092e859b6ed3fd88d77a24f5f0d969f175c278b935172f9022d6b94ccdb1a37ded1482bd36f15be4e3a8d04db00750f562e6fe217"
}